Marketed by AstraZeneca, Seroquel treats patients with bipolar disorder and schizophrenia. Seroquel balances certain chemicals in the brain to control mood swings associated with bipolar disorder and symptoms of schizophrenia. Unfortunately, many patients taking the drug have developed diabetes.
In Jan. 2004, the FDA advised AstraZeneca to include a warning about high blood sugar and diabetes. The warning also suggested patients beginning treatment with Seroquel undergo blood glucose testing. While some patients who stopped taking Seroquel returned to normal levels of blood sugar, some needed continued anti-diabetic treatment.
In Nov. 2006, the FDA sent AstraZeneca a letter stating the company’s promotional material included allegedly false information. The FDA claims AstraZeneca failed to highlight the risk of diabetes and other risk factors associated with Seroquel.